ADAGENE INC-ADR (ADAG) Stock Price, Forecast & Analysis
USA - NASDAQ:ADAG - US0053291078 - ADR
ADAG Key Statistics, Chart & Performance
The current stock price of ADAG is 1.58 USD. In the past month the price decreased by -17.28%. In the past year, price decreased by -26.85%.
ADAG Latest News, Press Relases and Analysis
ADAG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.14 | 386.36B | ||
| AMGN | AMGEN INC | 14.8 | 174.25B | ||
| GILD | GILEAD SCIENCES INC | 14.43 | 146.60B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.26 | 107.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.55 | 69.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 866.08 | 57.90B | ||
| INSM | INSMED INC | N/A | 40.57B | ||
| NTRA | NATERA INC | N/A | 28.36B | ||
| BIIB | BIOGEN INC | 9.33 | 22.91B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 20.53B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.89 | 14.88B |
Related stock screener links
About ADAG
Company Profile
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu and currently employs 138 full-time employees. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Company Info
ADAGENE INC-ADR
4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park
Suzhou JIANGSU 215123 CN
CEO: Peter (Peizhi) Luo
Employees: 138
Phone: 8651287773632
ADAGENE INC-ADR / ADAG FAQ
What does ADAG do?
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu and currently employs 138 full-time employees. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
What is the stock price of ADAGENE INC-ADR today?
The current stock price of ADAG is 1.58 USD. The price increased by 12.46% in the last trading session.
Does ADAG stock pay dividends?
ADAG does not pay a dividend.
How is the ChartMill rating for ADAGENE INC-ADR?
ADAG has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting ADAG stock to perform?
11 analysts have analysed ADAG and the average price target is 9.84 USD. This implies a price increase of 522.49% is expected in the next year compared to the current price of 1.58.
What is the market capitalization of ADAG stock?
ADAGENE INC-ADR (ADAG) has a market capitalization of 74.43M USD. This makes ADAG a Micro Cap stock.
ADAG Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ADAG. When comparing the yearly performance of all stocks, ADAG is a bad performer in the overall market: 83.86% of all stocks are doing better.
ADAG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADAG. ADAG may be in some trouble as it scores bad on both profitability and health.
ADAG Financial Highlights
Over the last trailing twelve months ADAG reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS increased by 10.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.94% | ||
| ROE | -78.84% | ||
| Debt/Equity | 0.06 |
ADAG Forecast & Estimates
11 analysts have analysed ADAG and the average price target is 9.84 USD. This implies a price increase of 522.49% is expected in the next year compared to the current price of 1.58.
For the next year, analysts expect an EPS growth of 13.69% and a revenue growth -17.84% for ADAG